Home › Therapeutic areas › Metabolic › Type 2 Diabetes
Type 2 Diabetes (7 companies)
Companies with an active program in Type 2 Diabetes.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| BLTE | Belite Bio | MetabolicOphthalmology Rare | 1 | NDA Submitted | $6.21B | 6 |
| BMEA | Biomea Fusion | MetabolicOncology | 1 | Phase 2 | $41.1M | 4 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | $647M | 12 |
| NAMS | NewAmsterdam Pharma | CardiovascularMetabolic+1 | 1 | NDA Submitted | $2.27B | 6 |
| GPCR | Structure Therapeutics | MetabolicRespiratory Rare | 1 | Phase 3 | $4.35B | 5 |
| VKTX | Viking Therapeutics | MetabolicNeurology Rare | 2 | Phase 3 | $3.42B | 9 |
| VTVT | vTv Therapeutics | HematologyMetabolic+1 Rare | 2 | Phase 3 | $84.4M | 9 |
No companies match.